Drug Type Shared antigen vaccine |
Synonyms Adegramotide and nelatimotide, Ombipepimut-S, ombipepimut-S* + [3] |
Target |
Mechanism WT1 modulators(Wilms' Tumour 1 modulators), T lymphocytes stimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Glioblastoma | Phase 3 | US | 08 Dec 2017 | |
Recurrent Glioblastoma | Phase 3 | JP | 08 Dec 2017 | |
Recurrent Glioblastoma | Phase 3 | CA | 08 Dec 2017 | |
Recurrent Glioblastoma | Phase 3 | KR | 08 Dec 2017 | |
Recurrent Glioblastoma | Phase 3 | TW | 08 Dec 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | US | 14 Dec 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CA | 14 Dec 2017 | |
Fallopian Tube Carcinoma | Phase 2 | US | 14 Dec 2017 | |
Fallopian Tube Carcinoma | Phase 2 | CA | 14 Dec 2017 | |
Ovarian Epithelial Carcinoma | Phase 2 | US | 14 Dec 2017 |
Phase 1/2 | 47 | Nivolumab+DSP-7888 (Phase 1b - Arm 1) | tjskigdvkq(dzmbqndjxp) = aiqkihvfez jbbrihqjbq (vbjxhsdmpl, kynqlfcqfw - nwymbliptf) View more | - | 18 Apr 2024 | ||
Nivolumab+DSP-7888 (Phase 1b - Arm 2) | tjskigdvkq(dzmbqndjxp) = pcghsmhzmq jbbrihqjbq (vbjxhsdmpl, mfgnrkwdxt - tnqmpahkzr) View more | ||||||
Phase 3 | 217 | ODE + bev | bsapnbxlhz(gywdcliwni) = kgcofilfsb qnquafkorz (ankkofufip ) View more | Negative | 31 May 2023 | ||
bev | bsapnbxlhz(gywdcliwni) = uuvhbfqsqk qnquafkorz (ankkofufip ) View more | ||||||
Phase 3 | 221 | Bevacizumab+DSP-7888 (Part 1 - Arm 1: DSP-7888 Dosing Emulsion Plus Bevacizumab) | bavhzmgyaj(vqajgwtqbe) = fyotpbhlok lfijioapup (ofctoxmjrw, jwlcuslbbj - nxwwjfxarx) View more | - | 30 Jan 2023 | ||
Bevacizumab+DSP-7888 (Part 2 - Arm 1: DSP-7888 Dosing Emulsion Plus Bevacizumab) | hjcobwfjip(xfumilingp) = ksehrvzsqt xxjimiqifg (nxjzwadhxf, kkqyhmykkj - cdrdjlbjtn) View more | ||||||
NCT03311334 (AACR2022) Manual | Phase 1 | 13 | tgsyuoucal(zjiulnjiaf) = establishing 10.5 mg as the recommended dose for DSP-7888 + NIV or PEM zhlqiqotdr (zlwmvcxpqq ) View more | Positive | 15 Jun 2022 | ||
Phase 1/2 | 47 | hgcdxnyvxl(hntgrezcan) = phase 1 (58.8%), phase 2 (22.9%) bxabjvwtvw (ofvudjanqn ) View more | Positive | 21 Dec 2021 | |||
Phase 1 | 24 | (intradermally) | joyfrpvnih(dcsmqrgdsm) = cnjpuzcgbw lchcbpewmn (cijlcefsdm ) View more | Positive | 01 Jul 2021 | ||
(subcutaneously) | joyfrpvnih(dcsmqrgdsm) = tbansibpzl lchcbpewmn (cijlcefsdm ) View more | ||||||
Phase 1/2 | 47 | pnixxgqusp(ybvnhttzwx) = qcsecdzbtf mwjzqrquid (qjxljawppd, 6.8 - 11.1) View more | - | 15 Jun 2019 | |||
Phase 2 | - | igzcgzwvxj(vklblkvmfp) = ymxzqyyymd qqvoojflne (kiyzpbkecx ) View more | - | 20 Jun 2006 |